MYCN amplification is a major biomarker of poor prognosis, occurring in 25-30% of neuroblastomas. MYCN has contradictory roles in promoting cell growth and sensitizing cells to apoptosis. We have recently shown that p53 is a direct transcriptional target of MYCN in neuroblastoma and that p53-mediated apoptosis may be an important mechanism of MYCN-induced apoptosis. Although p53 mutations are rare in neuroblastoma at diagnosis, the p53/MDM2/p14 ARF pathway is often inactivated through MDM2 amplification or p14 ARF inactivation. We hypothesized that reactivation of p53 by inhibition of its negative regulator MDM2, using the MDM2-p53 antagonists Nutlin-3 and MI-63, will result in p53-mediated growth arrest and apoptosis especially in MYCN-amplified cells. Using the SHEP Tet21N MYCN-regulatable system, MYCN(À) cells were more resistant to both Nutlin-3 and MI-63 mediated growth inhibition and apoptosis compared with MYCN( þ ) cells and siRNA-mediated knockdown of MYCN in four MYCN-amplified cell lines resulted in decreased p53 expression and activation, as well as decreased levels of apoptosis following treatment with MDM2-p53 antagonists. In a panel of 18 neuroblastoma cell lines treated with Nutlin-3 and MI-63, the subset amplified for MYCN had a significantly lower mean GI 50 value (50% growth inhibition) and increased caspase 3/7 activity compared with the non-MYCN-amplified group of cell lines, but p53 mutant cell lines were resistant to the antagonists regardless of MYCN status. We conclude that amplification or overexpression of MYCN sensitizes neuroblastoma cell lines with wild-type p53 to MDM2-p53 antagonists and that these compounds may therefore be particularly effective in treating high-risk MYCN-amplified disease.
Introduction
Neuroblastoma is an embryonal malignancy originating from developing neural crest cells, which go on to form the sympathetic nervous system. It is the most common solid extracranial malignancy of childhood (Maris et al., 2007) . Over 50% of cases of neuroblastoma are high risk and difficult to cure, with long-term survival rates remaining below 40% despite intense multimodal therapies. MYCN gene amplification is a major marker of adverse prognosis, occurring in 25-30% of neuroblastomas and is strongly associated with progressive disease and treatment failure (Cohn and Tweddle, 2004) . Infants under 18 months with MYCN-amplified tumors have an event-free survival of 26% compared with 83% for infant stage 4 patients without MYCN amplification (Cohn et al., 2009) .
MYCN belongs to the MYC family of transcription factors that have roles in promoting cell proliferation, differentiation, oncogenesis and apoptosis (Kang et al., 2006) . These proteins transcriptionally activate target genes by forming heterodimers with MAX, which bind to the promoters of target genes, typically at E-box sequences (Wenzel et al., 1991) . MYCN expression alone, targeted to developing neural crest tissue, has been shown to directly result in neuroblastoma tumor formation in transgenic mice (Weiss et al., 1997) , and there is evidence that MYCN expression sensitizes neuroblastoma cells to apoptosis induced by cytotoxic drugs (Fulda et al., 2000; Hogarty, 2003) . However, as patients with MYCN-amplified tumors have such an inferior outcome, acquired aberrations in the apoptotic pathway are thought to be associated with MYCN amplification and to be essential for tumor progression.
p53 is a critical tumor suppressor gene that is mutated in over 50% of adult sporadic cancers. It has a major role in protecting the cell from genomic instability and tumor development by inducing apoptosis and cell cycle arrest in response to cellular stresses and DNA damage (reviewed in Michalak et al., 2005) . In neuroblastoma, p53 mutations are rare, occurring in o2% of cases at diagnosis and B15% at relapse (Carr-Wilkinson et al., 2010) . However, in 1/3 cases in a study of relapsed tumors, p53 was found to be inactivated via other mechanisms that resulted in destablization of p53 or disruption of p53 activity (Carr-Wilkinson et al., 2010) .
In neuroblastoma, other mechanisms of p53 inactivation include amplification of the E3 ubiquitin ligase gene MDM2, or impairment of p14 ARF , a negative regulator of MDM2 Carr-Wilkinson et al., 2010) . MDM2 is the major negative regulator of p53 activity and stability, promoting the ubiquitination and degradation of p53 but also blocking its transcriptional activity by binding to the transactivation domain within the N-terminal of p53. MDM2 is also a transcriptional target of p53, forming a negative feedback loop that allows for tight regulation of p53 under normal circumstances. Non-syntenic co-amplification of MDM2 and MYCN has been reported in neuroblastoma cell lines and tumors, resulting in constant negative regulation of p53 (Corvi et al., 1995; Carr-Wilkinson et al., 2010) . More commonly in tumors, p14 ARF function is impaired through methylation or homozygous deletion of the gene (Carr-Wilkinson et al., 2010) . p14 ARF negatively regulates MDM2 and therefore p14 ARF inactivation drives cell survival through increased MDM2 activity. MYCN is a central modulator of the p53/MDM2/p14 ARF network. There is evidence that both p53 and MDM2 are direct transcriptional targets of MYCN Chen et al., 2010) , and that p53 may be important for MYCN-induced apoptosis (Chen et al., 2010) . It has also been reported that p14
ARF is activated by c-MYC (Zindy et al., 1998) , and due to the similarities between MYCN and c-MYC, MYCN may function in a similar way. MDM2 haploinsufficiency in mice has been shown to suppress MYCN-driven neuroblastoma tumorigenesis (Chen et al., 2009) , and there is evidence that MDM2 may be the critical oncogene by which MYCN-amplified neuroblastomas acquire an aggressive phenotype (Slack and Shohet, 2005) . As MYCN amplification is thought to be associated with defects in activating or executing apoptotic pathways and that this may be related to overactive MDM2, we hypothesize that MYCN-amplified tumors may be more susceptible to compounds that reactivate p53. Several studies have shown that the downstream apoptotic pathway of p53 is generally intact in neuroblastoma (Goldman et al., 1996; Hogarty, 2003) .
The hydrophobic p53-binding pocket of MDM2 is ideal for developing low molecular weight compounds that occupy the pocket and prevent p53 from binding. Compounds have been developed that induce cell cycle arrest and apoptosis in cancer cells, but usually only produce reversible growth arrest in normal cells (Vassilev et al., 2004; Efeyan et al., 2007) . Nutlin-3 is a cis-imidazoline analogue that binds MDM2 at the p53-binding site with a K i of 36 nM (Vassilev et al., 2004) and MI-63, a spiro-oxindole, is more potent, binding MDM2 with a K i of 3 nM (Canner et al., 2009) . In wild-type p53 neuroblastoma cell lines, Nutlin-3 has been reported to induce cell cycle arrest and apoptosis, and surviving cells underwent senescence or neuronal differentiation in cell lines tested, however, the relationship to MYCN status was not extensively explored (Van Maerken et al., 2006) . Although not previously investigated in neuroblastoma or in relation to MYCN, MI-63 has also been shown to induce apoptosis in cell lines with wild-type p53 (Canner et al., 2009) .
The current study provides evidence that MYCN expression sensitizes neuroblastoma cells to MDM2-p53 antagonists. We show that (a) in a MYCN-regulatable cell line (Tet21N), MYCN( þ ) cells are more sensitive to MDM2-p53 antagonist mediated growth inhibition and apoptosis than MYCN(À) cells, (b) siRNA-mediated knockdown of MYCN results in a decreased p53 response and decreased induction of apoptosis by MDM2-p53 antagonist treatment, and (c) in a panel of 18 cell lines, MYCN-amplified cells are more sensitive to Nutlin-3 and MI-63 than non-MYCN-amplified cell lines. GI 50 values are shown in Table 1 . As a control, growth inhibition assays were performed in Tet21 vector-only cells and no difference in GI 50 was observed.
Results

MYCN(À)
As previously reported MYCN( þ ) cells have a doubling time of 78.5 h compared with 90.4 h for MYCN(À) cells . This difference in growth rate is reflected in the higher proportion of MYCN(À) cells in G 1 compared with MYCN( þ ) cells, which have a greater proportion of cells in S and G 2 phases (Figure 1c ). Upon 2.5 mM Nutlin-3 and MI-63 treatment, both MYCN( þ ) and MYCN(À) cells undergo G 1 arrest, but this effect is more pronounced in MYCN( þ ) cells due to the lower G 1 baseline proportions. Interestingly, there is an increase in the proportion of cells in G 2 at 10 mM Nutlin-3 and MI-63 in both MYCN( þ ) and MYCN(À) cells.
Three techniques were used to investigate levels of apoptosis following Nutlin-3 or MI-63 treatment in Tet21N cells. As shown in Figure 2a WAF1 or MDM2 levels either decreased or didn't change and in all cases, a decrease in at least two of the apoptotic markers PUMA, cleaved caspase 3 and cleaved PARP was observed.
Apoptosis following MYCN knockdown and MDM2-p53 antagonist treatment was further investigated in TR14, LAN5 and LS cells. Caspase 3/7 activity assays were performed for TR14 and LAN5 cells (Figures 3b and 4b ). After Nutlin-3 or MI-63 treatment, a dose-dependent increase in caspase 3/7 activity was seen in both cell lines with both compounds (Figures 3b and 4b) , and an increase in sub G 1 DNA % in LS cells (Supplementary Figure S1B) . Following MYCN knockdown, there was a reduction in caspase 3/7 activity in TR14 and LAN5 cells (Figures 3b and 4b at 0 mM) compared with SCR control, and a significant reduction in caspase activity was observed in both TR14 and LAN5 cell lines following MYCN knockdown and Nutlin-3 or MI-63 treatment, (TR14 P ¼ 0.0015 Nutlin-3, P ¼ 0.0001 MI63; LAN5 P ¼ 0.0026 Nutlin-3, P ¼ 0.008 MI-63). Levels of sub G 1 DNA in LS cells (Supplementary Figure S1B) reduced after MYCN knockdown following Nutlin-3 (P ¼ 0.08) and MI-63 (Po0.05) treatment compared with SCR. These data are consistent with the reduction in levels of apoptotic markers shown by western blot showing that removal of MYCN by siRNA knockdown results in a decreased apoptotic response to MDM2-p53 antagonists.
Knockdown of MYCN does not alter the cell cycle response to MDM2-p53 antagonists The effect of MDM2-p53 antagonists on the cell cycle was investigated in TR14, LAN5 and LS cells. TR14 cells underwent a slight G 1 arrest upon Nutlin-3 or MI-63 treatment (Figure 3c ), whereas LAN5 ( Figure 4c ) and LS (Supplementary Figure S1C) cells did not arrest. Knockdown of MYCN induced a G 1 arrest in both TR14 and LS cells, but the effect of MDM2-p53 antagonists was not influenced by MYCN knockdown. This data suggest that upon MDM2-p53 antagonist treatment, some neuroblastoma cell lines undergo G 1 arrest and that the effect is cell line dependent, but the response is not altered upon MYCN knockdown.
MYCN-amplified neuroblastoma cell lines are more sensitive to MDM2-p53 antagonist mediated growth inhibition than non-MYCN-amplified neuroblastoma cell lines Induction of a p53 response from MDM2-p53 antagonists can initiate a number of effects, including two important anti-tumor responses, cell cycle arrest and apoptosis. A panel of 12 MYCN-amplified (including four MYCN and MDM2 co-amplified) and 8 non-MYCN amplified neuroblastoma cell lines were investigated for their sensitivity to Nutlin-3 and MI-63 mediated growth inhibition, which takes into account both growth arrest and cell death. GI 50 values for all p53 wild-type cell lines are shown in Table 1 . In response to Nutlin-3 (Figures 5a and 5bi ) and MI-63 (Figures 5c and 5di), MYCN-amplified neuroblastoma cell lines underwent more growth inhibition compared with nonamplified cell lines with a significant difference in mean GI 50 s (Po0.001 for Nutlin-3 and Po0.05 for MI-63). Overall a more varied response to the antagonists was seen in the non-amplified cell lines compared with MYCN-amplified cell lines. Interestingly, the p53 wildtype SKNRA cell line was most resistant to both Nutlin-3 and MI-63. MYCN-only-amplified cell lines were also more sensitive to Nutlin-3 mediated growth inhibition compared with MYCN and MDM2-co-amplified neuroblastoma cell lines (Figure 5bii ) (Po0.01) and although this difference did not reach statistical significance, the same trend was observed for MI-63 (Figure 5dii) . A number of cell lines in this panel had impaired p14
ARF function: PER-108 (methylated) and GIMEN (methylated), SHEP (homozygous deletion) and LAN-6 (homozygous deletion) . There appeared to be a varied response to MDM2-p53 antagonist mediated growth inhibition with no evidence that p14 ARF status affects the response to these compounds. Two MYCN-amplified p53 mutant cell lines (Be2C and IGRN91) and one non-MYCNamplified p53 mutant cell line (SKNAS) were investi- gated for their sensitivity to Nutlin-3 and MI-63. As shown in Figure 5e , p53 mutant cell lines were highly resistant to these compounds regardless of MYCN status. Growth inhibition of 50% was not achieved in these cell lines with the highest concentrations of Nutlin-3 (20 mM) and MI-63 (10 mM) used to generate GI 50 values in the other p53 wild-type cell lines tested.
MYCN-amplified neuroblastoma cell lines are more sensitive to MDM2-p53 antagonist mediated apoptosis compared with non-MYCN-amplified neuroblastoma cell lines As a marker of apoptosis, caspase 3/7 activity following Nutlin-3 or MI-63 treatment was determined in the same panel of neuroblastoma cell lines that were assessed for growth inhibition. In response to 5 mM Nutlin-3 ( Figure 6a ) and 2.5 mM MI-63 (Figure 6b ), MYCNamplified neuroblastoma cell lines showed higher mean caspase 3/7 activity compared with non-MYCN-amplified cell lines (P ¼ 0.0343 for Nutlin-3 and P ¼ 0.0085 for MI-63). Interestingly, despite no obvious resistance to growth inhibition, p14 ARF -impaired cell lines, particularly those that are not MYCN amplified, appear to be especially resistant to MDM2-p53 antagonist mediated activation of caspase 3/7 activity, which was comparable to that of p53 mutant cell lines (Figure 6c ). In addition, the MYCN and MDM2-co-amplified cell lines that display increased caspase 3/7 activity have been previously reported to express high levels of p14 ARF mRNA and protein .
Discussion
Neuroblastoma accounts for 15% of childhood cancerrelated deaths (Maris and Matthay, 1999) . MYCN amplification is a powerful and reliable biomarker of poor prognosis in neuroblastoma and is used to stratify patients into a high-risk group requiring intensive treatment. However, current therapies are insufficient for these patients, resulting in high mortality rates, a high incidence of relapse and treatment related toxicity .
MYCN has roles in the contradictory pathways of promoting both cell survival (Lutz et al., 1996) and sensitizing cells to apoptosis (Fulda et al., 2000; van Noesel et al., 2003) , but in neuroblastomas abnormalities within the apoptotic pathways can occur in association with MYCN amplification (Hogarty, 2003) . p53, the major tumor suppressor in the cell, is generally wild type and active at diagnosis and patients respond well to initial therapy. However, high-risk patients often relapse and although p53 mutations are still relatively rare (B15% of cases), p53 function is often inactivated through disruption of the p53/MDM2/p14 ARF network, of which MYCN is a central modulator (Figure 7) , resulting in chemoresistant disease (Carr-Wilkinson et al., 2010) . A number of studies have shown that pathways downstream of p53 are intact in neuroblastoma and that p53 can induce apoptotic responses (Vogan et al., 1993; Hosoi et al., 1994; Hogarty, 2003; Tweddle et al., 2003) . However, in response to DNA damage, MYCN-amplified cell lines fail to undergo G 1 arrest compared with non-amplified cell lines . In response to Nutlin-3 and MI-63 we found that changes in cell cycle distribution were cell line dependent. It has been previously reported that the negative regulator of p53, MDM2, is the critical oncogene product by which MYCN-amplified neuroblastomas acquire a more aggressive behavior (Slack and Shohet, 2005) , and that MYCN and MDM2 work together to inhibit apoptosis (Alt et al., 2003; Wang et al., 2006) . There are a number of mechanisms by which MDM2 might contribute to the aggressive phenotype of MYCNamplified neuroblastoma. MDM2 has been reported to be a direct transcriptional target of MYCN and therefore MYCN-driven expression of MDM2 may contribute to p53 inactivation in neuroblastoma . MDM2 is co-amplified with MYCN in about 6% of neuroblastomas but more frequently the negative regulator of MDM2, p14 ARF is inactivated through methylation or deletion, and has been reported to occur in 29% of tumors, resulting in hyperactive MDM2 (Corvi et al., 1995; Carr-Wilkinson et al., 2010) . In addition, we have recently reported that p53 is a direct transcriptional target of MYCN, and that p53 induction by MYCN may be an important contributory mechanism by which MYCN sensitizes cells to apoptosis (Chen et al., 2010) .
Here we investigate the effect of MYCN on the response to the MDM2-p53 antagonist Nutlin-3 and the more potent MI-63, not previously investigated in neuroblastoma. We show by three independent methods that MYCN amplification and expression sensitizes neuroblastoma cell lines to MDM2-p53 antagonists. First, using the SHEP Tet21N MYCN-regulatable cell line, both Nutlin-3 and MI-63 are more effective at inducing growth inhibition and apoptosis in MYCN( þ ) compared with MYCN(À) cells, as shown by growth inhibition assays, caspase 3/7 activity, the sub G 1 DNA Figure 5 MYCN-amplified neuroblastoma cell lines are more sensitive to MDM2-p53 antagonists than non-MYCN-amplified neuroblastoma cell lines. A panel of neuroblastoma cell lines were treated with (a, b) Nutlin-3 and (c, d) MI-63 with doses ranging from 0-20 mM and 0-10 mM, respectively, to obtain GI 50 s. A significant difference was observed between GI 50 s for both (bi) Nutlin-3 (Po0.001) and (di) MI-63 (Po0.05). There was an increase in GI 50 s in MYCN and MDM2-co-amplified cell lines compared with MYCN-only-amplified cell lines for (bii) Nutlin-3 (Po0.01) but not (dii) MI-63 (P ¼ 0.07). Mann-Whitney tests were used to calculate P-values. (e) p53 mutant cell lines including one non-amplified and two MYCN amplified were treated with up to 20 mM Nutlin-3 and 10 mM MI-63. All three cell lines were resistant to Nutlin-3 and MI-63 compared with wild-type p53 cell lines. Cell lines marked * are p14 ARF impaired (methylation or homozygous deletion).
content on fluorescence-activated cell sorting analysis and induction of the p53 regulated apoptotic marker PUMA. Second, we show that following siRNA knockdown of MYCN in two MYCN-amplified and two MYCN and MDM2-co-amplified neuroblastoma cell lines, Nutlin-3 and MI-63 treatment resulted in a decreased p53 response and decreased levels of apoptosis. Third, we assessed growth inhibition and caspase activity in a panel of 18 cell lines and found that both Nutlin-3 and MI-63 were more effective at inducing growth inhibition and apoptosis in MYCN-amplified cells compared with non-MYCN-amplified cells. We also show that the effect is dependent on wild-type p53 in both MYCN-amplified and non-amplified cell lines, consistent with a number of reports showing that these compounds require wild-type p53, as expected if their action is target-specific (Vassilev et al., 2004; Van Maerken et al., 2006) . All MYCN-amplified cell lines investigated were responsive to MDM2-p53 antagonists, whereas the response of non-amplified cell lines was more variable. This is unsurprising as MYCN amplification is directly responsible for transformation; nonamplified cases are likely to have a variety of other genetic abnormalities or defects in apoptotic pathways that may not be present in MYCN-amplified tumors.
Our data differs from previous findings that report no correlation between MYCN status and response to Nutlin-3 (Barbieri et al., 2006; Van Maerken et al., 2006) . Van Maerken et al. tested a panel of seven p53 wild-type cell lines (three MYCN amplified), and found no significant difference in the cell viability response or apoptotic response to Nutlin-3 in MYCN-amplified compared with non-MYCN-amplified cell lines (Van Maerken et al., 2006) . In another study half maximal inhibitory concentration values for Nutlin-3 in two MYCN-regulatable cell lines were determined and although in agreement with our extensive observations that there was increased sensitivity in MYCN( þ ) compared with MYCN(À) Tet21 cells, it was reported that there was no difference in half maximal inhibitory concentration values for MYCN( þ /À) MYCN3 cells (Barbieri et al., 2006) . To test the effect of MYCN on sensitivity to MDM2-p53 antagonists, we used several methods and a total of 22 cell lines to investigate the influence on cell growth and cell death, and found similar results using two structurally unrelated MDM2-p53 antagonists. Furthermore, previous studies with Tet21N cells have reported that MYCN( þ ) cells were more sensitive to apoptosis from cytotoxic drugs than MYCN(À) cells (Fulda et al., 2000) , and a recent study reports that MYCN sensitizes neuroblastoma cell lines to the apoptotic effects of bleomycin (Petroni et al., 2011) , in agreement with our data that MYCN is sensitizing cells to apoptosis. p14 ARF is often inactivated in neuroblastoma (Carr-Wilkinson et al., 2010) , expressed at higher levels in MYCN and MDM2-coamplified neuroblastoma cell lines than MYCN-amplified and non-MDM2-amplified cell lines , and may inhibit MYCN transcriptional activity (Amente et al., 2007) . There is also evidence that p14 ARF is induced by c-MYC, and therefore MYCN may function in a similar way (Zindy et al., 1998) . Interestingly the three non-MYCN-amplified p14 ARF -impaired cell lines were especially resistant to Nutlin-3 and MI-63 mediated apoptosis, supporting recent findings showing that silencing of p14 ARF results in decreased susceptibility to undergo apoptosis and overexpression of p14 ARF results in a stronger caspase 3/7 response (Van Maerken et al., 2011) .
We found that MYCN and MDM2-co-amplified neuroblastomas had reduced sensitivity to Nutlin-3 mediated growth inhibition, and a similar trend with MI-63, compared with MYCN-only-amplified cell lines. However, we saw increased levels of caspase 3/7 activity in these cell lines compared with MYCN-amplified and non-amplified cell lines, consistent with previous reports that increased levels or amplification of MDM2 increases Nutlin-3 induced apoptosis as shown in liposarcomas and AML (Kojima et al., 2005; Muller et al., 2007) . However, MYCN and MDM2-co-amplified cell lines have previously been reported to have increased p14
ARF mRNA and protein expression , and it may be this increase in p14 ARF that is sensitizing these cell lines to increased caspase activity. Our data indicate that MDM2 co-amplification may increase the resistance of MYCN-amplified neuroblastomas to Nutlin-3 mediated growth inhibition but may sensitize to apoptosis, and therefore the effect of MDM2 warrants further investigation.
Our observations support studies that both MDM2 and p53 are induced by MYCN, MDM2 is a critical oncogene product by which MYCN-amplified neuroblastomas acquire a more aggressive phenotype and MYCN sensitizes cells to p53-mediated apoptosis. Under normal circumstances, both p53 and MYCN induce MDM2, but upon MDM2 inhibition MYCN-mediated transcription of p53 allows p53 to accumulate and increases its activity. In addition, there is evidence that both p53 and c-MYC inhibit anti-apoptotic factors such as Bcl-2 and Bcl-x, another mechanism by which amplification of MYCN may promote apoptosis together with p53 if, as is likely, this is also true of MYCN (van Noesel and Versteeg, 2004; Chipuk and Green, 2006) . Interestingly, p53 has been shown to inhibit the mammalian target of rapamycin (mTOR) pathway that is involved in senescence , and there is evidence that p53-induced cell cycle arrest is reversible as long as mTOR is also inhibited, suggesting that induction of senescence, reversible cell cycle arrest and cell death in response to Nutlin-3 may be determined by the status of mTOR . The activation status of mTOR may therefore be important in determining the response to MDM2-p53 antagonists in neuroblastoma.
In conclusion, we have several lines of evidence that MYCN sensitizes neuroblastoma cell lines to MDM2-p53 antagonists through p53-dependent growth inhibition and apoptosis, and may provide a promising therapeutic approach for patients with high-risk MYCN-amplified neuroblastoma with wild-type p53. Previous studies show that MYCN amplification sensitizes cells to chemotherapeutic drugs and that Nutlin-3 induces senescence in normal cells that might actually protect the cell against cytotoxic drugs (Fulda et al., 2000; Efeyan et al., 2007) . Furthermore, Nutlin-3 synergizes with chemotherapy in neuroblastoma cells (Barbieri et al., 2006) suggesting that patients with MYCN-amplified tumors may be particularly responsive to MDM2-p53 antagonists in combination with chemotherapeutic drugs.
Materials and methods
Cell lines and reagents MYCN-amplified neuroblastoma cell lines used in this study were NGP, LS, TR14, NB1691, IMR-32, NBLW, SMSKCNR, LAN5, PER-108, CHLA136, and the p53 mutant cell lines SKNBe2C and IGRN91. Non-MYCN-amplified cell lines used were SHSY5Y, GIMEN, SJNB1, NB69, LAN6, SKNRA, SHEP, NBLS and the p53 mutant cell line SKNAS. The conditional MYCN-expressing SHEP Tet21N cell line was used and cells were cultured for at least 48 h in 1 mg/ml of tetracycline (Sigma, Dorset, UK) to switch off MYCN. Tet21 vector-only cells were used as a control (Lutz et al., 1996) . All cell lines were cultured in RPMI medium (Sigma) supplemented with 10% fetal calf serum, and 200 mg/ml of G-418 antibiotic was added to Tet21N and Tet21 media. Cell lines were validated upon receipt using cytogenetic analysis courtesy of Nick Bown, Institute of Human Genetics, Newcastle University, UK. Nutlin-3 was purchased from Enzo Life Sciences (Exeter, UK) and MI-63 was kindly provided by Siena Biotech (Siena, Italy) as part of a Framework Programe 6 DePPICT consortium collaboration.
Growth inhibition assays
Cells were plated in 96-well plates (Corning, UK) for 24 h before treatment with 0-20 mM Nutlin-3 or 0-10 mM MI-63 for 72 h. Cells were then fixed in 50% trichloroacetic acid, and sulphorhodamine B assays performed as previously described (Skehan et al., 1990) . A SpectroMax 250 (Molecular Devices, Berkshire, UK) was used for densitometric scanning of the plates and GI 50 values were calculated using GraphPad Prism Version 4.0 software (GraphPad Software, Inc., San Diego, CA, USA).
RNA interference
Cells were seeded at 4 Â 10 5 cells/well in 6-well plates (Corning, Amsterdam, The Netherlands). At 30-50% confluency, 40 nM (NGP, LS, IMR32) or 50 nM (LAN5) of siRNA duplexes against MYCN were transfected into cells with Lipofectamine reagent (Invitrogen, Paisley, UK) using previously described sequences , for 24 h. All experiments were performed in triplicate.
Western analysis
Previously described methods were used with 25 mg of protein (Tweddle et al., 2001) . Primary antibodies used were MYCN (Calbiochem, Nottingham, UK; OP13), MDM2 (Calbiochem; OP40), p21 WAF1 (Calbiochem; OP68), PARP-1/2 (Santa Cruz, CA, USA; H-250), at 1:100, p53 (Novocastra, Newcastle, UK; DO-7) at 1:200, Phospho-p53(Ser15) (Cell signalling, Danvers, MA, USA; 9284) and Cleaved Caspase-3 (Cell Signalling; Asp175) at 1:1000, and b-actin (Sigma-Aldrich, Dorset, UK; AC-40) at 1:500. Secondary goat anti-mouse/rabbit (Dako, Glostrup, Denmark) antibodies conjugated to horseradish peroxidase were used at 1:1000.
Flow cytometry
For cell cycle and sub-G 1 analysis, adherent and non-adherent cells were harvested, washed in phosphate-buffered saline and fixed in 4:1 methanol-acetone solution. Fluorescence-activated cell sorting analysis was performed using previously described methods . The Becton Dickinson FACscan was used and data were analyzed using CellQuest software (Becton Dickinson, Mansfield, MA, USA).
Caspase activity A total of 5000 cells/well were seeded in 96-well plates. After treatment, a 1:1 volume of Caspase-Glo 3/7 reagent (Promega, Southhampton, UK) was added to wells for 1 h, transferred to a white plate and then analyzed on a microplate Luminometer (Berthold Technologies, Herefordshire, UK).
Statistical analyses
All statistical tests were performed in GraphPad Prism (GraphPad Software, Inc.). Tests were performed using log values and all t-tests were two-sided.
